ProJect Pharmaceutics
Martinsried, Germany project-pharmaceutics.com
From their website, Nov 2026
Work here? Claim this listing
- GLP
- GMP
About
ProJect Pharmaceutics GmbH develops formulations and manufacturing processes for injectable therapeutic products. It works with recombinant proteins, antibodies, ADCs, peptides, small molecules, viral vectors, liposomes, and nanoparticle systems for preclinical through commercial development. The company is based in Martinsried, Munich, Germany, with business development representation in Boston, MA.
Services
Formulation development
Develops liquid and lyophilized injectable formulations for proteins, antibodies, peptides, ADCs, small molecules, and viral and nanoparticle systems.
Assays & in vitro testing
Preformulation screening
Screens physicochemical properties and formulation variables to identify stable and developable lead formulations.
Assays & in vitro testing
High concentration & subcutaneous formulation
Develops high-concentration formulations for subcutaneous delivery.
Assays & in vitro testing
Lyophilization cycle development
Develops freeze-drying cycles for client formulations and manufacturer equipment.
Downstream process development
Develops purification and UF/DF steps around molecule stability and delivers drug substance in a usable formulation.
Analytical services & method development
Runs and develops analytical methods for biologics, ADCs, cytotoxics, and viral therapeutics, including method implementation and optimization.
Assays & in vitro testing
Forced degradation & stress studies
Stresses lead formulations to identify degradation pathways and support formulation selection and method development.
Assays & in vitro testing
In-use stability & clinical administration
Simulates site preparation, dilution, holding, infusion, and injection to assess in-use stability and administration compatibility.
Assays & in vitro testing
Technology transfer to fill & finish
Develops formulations and fill-finish processes for transfer to a manufacturer’s filling line.
Non-GMP toxicology & stability batches
Makes aseptic non-GMP preclinical batches of liquid or lyophilized product for toxicology, PK/PD, and stability studies.
CDMO: development & manufacturing
- Turnaround
- Within 5 days reporting of analytical results · Within 5 days reporting of results after testing · 2 to 4 weeks from scope alignment to project start · 5 to 6 weeks of cycle development
- What to send
- Final formulation · Container · Fill volume · Information on your manufacturer’s dryer · Target product profile · Intended manufacturer, if known
Capabilities
- Assays and studies
- Lyophilization · ADCs · Toxicology · Process development · Antibodies · Fill-finish · Peptides · Small molecules · Bispecifics · Stability studies · SE-HPLC · AF4
11 more
DLS · nanoDSC · CG-MALS · cIEF · icIEF · IEX-HPLC · Electrophoresis · Light scattering · Calorimetry · Chromatography · Electron microscopy - Scale and capacity
- Up to 1,000 vials per batch · ~1,000 2R vials per biologics batch · 2R to 100H vial sizes · Up to OEB5 cytotoxic containment
- Therapeutic areas
- Biologics · ADCs · Cytotoxics · Viral therapeutics · Live viral vaccines
Instruments and platforms
- HOF pilot freeze-dryers
- Wyatt Technology
Modalities and species
- Modalities
- Small molecule · Antibody · Bispecific · ADC · Peptide · Viral vector · Recombinant protein · Vaccine · LNP / formulation
Certifications
As the company states them, with the certificate or registry record where there is one.
GLPSelf-reported
As listed: GLP-like documentation
GMPSelf-reported
Company
- Type
- CDMO
- Founded
- 2010
Locations
- Address
- manufacturing 250+ short- and long-term stability runs completed 140 lyophili
- Sites
- Martinsried, Germany · Munich, Germany · Boston, MA, United States
Contacts
- General enquiry
- info@project-pharmaceutics.com on their site
Similar labs
Work here? Claim this listing